- Home
- ARQQ vs MGNX Comparison
ARQQ vs MGNX Comparison
Compare ARQQ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- MGNX
- Stock Information
- Founded
- ARQQ 2017
- MGNX 2000
- Country
- ARQQ United Kingdom
- MGNX United States
- Employees
- ARQQ N/A
- MGNX N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ARQQ Technology
- MGNX Health Care
- Exchange
- ARQQ Nasdaq
- MGNX Nasdaq
- Market Cap
- ARQQ 282.1M
- MGNX 257.3M
- IPO Year
- ARQQ N/A
- MGNX 2013
- Fundamental
- Price
- ARQQ $29.12
- MGNX $3.00
- Analyst Decision
- ARQQ Strong Buy
- MGNX Hold
- Analyst Count
- ARQQ 1
- MGNX 10
- Target Price
- ARQQ $52.00
- MGNX $7.17
- AVG Volume (30 Days)
- ARQQ 1.4M
- MGNX 496.5K
- Earning Date
- ARQQ 12-05-2024
- MGNX 03-06-2025
- Dividend Yield
- ARQQ N/A
- MGNX N/A
- EPS Growth
- ARQQ N/A
- MGNX N/A
- EPS
- ARQQ N/A
- MGNX N/A
- Revenue
- ARQQ $293,000.00
- MGNX $141,329,000.00
- Revenue This Year
- ARQQ $1,818.77
- MGNX $174.73
- Revenue Next Year
- ARQQ N/A
- MGNX N/A
- P/E Ratio
- ARQQ N/A
- MGNX N/A
- Revenue Growth
- ARQQ N/A
- MGNX 16.68
- 52 Week Low
- ARQQ $3.72
- MGNX $2.91
- 52 Week High
- ARQQ $52.79
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- ARQQ 51.99
- MGNX 37.54
- Support Level
- ARQQ $15.60
- MGNX $3.00
- Resistance Level
- ARQQ $32.63
- MGNX $3.22
- Average True Range (ATR)
- ARQQ 6.42
- MGNX 0.17
- MACD
- ARQQ -1.37
- MGNX -0.02
- Stochastic Oscillator
- ARQQ 42.91
- MGNX 13.04
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).